{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:17:23Z","timestamp":1770797843503,"version":"3.50.0"},"reference-count":146,"publisher":"The Pediatric Pharmacy Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>\n                    The purpose of this review is to define \u201cneonatal selective serotonin reuptake inhibitor (SSRI) withdrawal syndrome\u201d (NSWS) from a developmental perspective and outline its management strategies as described in the current body of literature, with a focus on pharmaceutical interventions. A literature search was conducted with PubMed, OVID Medline, Google Scholar, Embase, and Web of Science. Search terms included\n                    <jats:italic>neonatal<\/jats:italic>\n                    and\n                    <jats:italic>SSRI<\/jats:italic>\n                    combined with the Boolean operator \u201cAND\u201d coordinated with the terms\n                    <jats:italic>withdrawal<\/jats:italic>\n                    ,\n                    <jats:italic>poor neonatal adaptation<\/jats:italic>\n                    , and\n                    <jats:italic>neonatal abstinence syndrome<\/jats:italic>\n                    . Non-pharmacologic interventions include appropriate hydration, nutrition, and providing a quiet and soothing environment for the infant. Most treatment algorithms for neonatal withdrawal syndromes involve\n                    <jats:italic>in utero<\/jats:italic>\n                    exposure to opioids and other psychotropics, and it is rare to find one that outlines specific guidelines for the management of NSWS. Symptomatic pharmacologic management should be individualized to the patient. Potential measures can include the administration of clonidine for tachycardia, hypertension, diaphoresis, and restlessness; phenobarbital for seizures; or chlorpromazine for agitation and irritability. There is generally no role for the use of morphine or methadone in the treatment of NSWS without combined exposure to opioids\n                    <jats:italic>in utero<\/jats:italic>\n                    . Without studies specifically designed to understand NSWS and guidelines on treatment, there is a lack of clarity regarding the management of neonates with this syndrome. There are limited data differentiating NSWS from neonatal opioid withdrawal despite these disease states being caused by different pharmaceutical agents. There needs to be clear and comprehensive guidelines inclusive of newer studies and comparative treatment efficacies to promote evidence-based practices surrounding NSWS.\n                  <\/jats:p>","DOI":"10.5863\/jppt-24-00010","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T13:56:53Z","timestamp":1750946213000},"page":"323-331","source":"Crossref","is-referenced-by-count":0,"title":["A Review of Neonatal Selective Serotonin Reuptake Inhibitor Withdrawal Syndrome"],"prefix":"10.5863","volume":"30","author":[{"given":"Likitha","family":"Mamillapalli","sequence":"first","affiliation":[{"name":"Department of Pharmacy (LM), Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Department of Pharmacy Practice and Administration (LM, SL, JW, RG, AC, KM, JG, AS, MS), Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration (LM, SL, JW, RG, AC, KM, JG, AS, MS), Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Witkin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration (LM, SL, JW, RG, AC, KM, JG, AS, MS), Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Gavaskar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration (LM, SL, JW, RG, AC, KM, JG, AS, MS), Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration (LM, SL, JW, RG, AC, KM, JG, AS, MS), Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"},{"name":"Department of Pharmacy (AC), Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaila","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration (LM, SL, JW, RG, AC, KM, JG, AS, MS), Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily Rita","family":"Aboujaoude","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice (ERA), D\u2019Youville University, Buffalo, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration (LM, SL, JW, RG, AC, KM, JG, AS, MS), Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"},{"name":"Department of Pharmacy (JG, AS), Jersey Shore University Medical Center, Neptune, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Siu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration (LM, SL, JW, RG, AC, KM, JG, AS, MS), Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"},{"name":"Department of Pharmacy (JG, AS), Jersey Shore University Medical Center, Neptune, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Sturgill","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration (LM, SL, JW, RG, AC, KM, JG, AS, MS), Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"},{"name":"Department of Pediatrics (MS), Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"3","key":"i2331-348X-30-3-323-b01","series-title":"Gen Hosp Psychiatry","first-page":"265","article-title":"National trends in antidepressant medication treatment among publicly insured pregnant women","volume":"35","author":"Huybrechts","year":"2013","unstructured":"Huybrechts KF, Palmsten K, Mogun H, et al. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry. 2013;35(3):265\u2013271."},{"key":"i2331-348X-30-3-323-b02","series-title":"J Affect Disord","first-page":"86","article-title":"A systematic review and meta-regression of the prevalence and incidence of perinatal depression","volume":"219","author":"Woody","year":"2017","unstructured":"Woody CA, Ferrari AJ, Siskind DJ, et al. A systematic review and meta-regression of the prevalence and incidence of perinatal depression. J Affect Disord. 2017;219:86\u201392."},{"issue":"11","key":"i2331-348X-30-3-323-b03","series-title":"Can J Psychiatry","first-page":"726","article-title":"Perinatal risks of untreated depression during pregnancy","volume":"49","author":"Bonari","year":"2004","unstructured":"Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49(11):726\u2013735."},{"issue":"2","key":"i2331-348X-30-3-323-b04","series-title":"Prim Care Companion CNS Disord","article-title":"Diagnosing and treating depression during pregnancy","volume":"17","author":"Wichman","year":"2015","unstructured":"Wichman CL, Stern TA. Diagnosing and treating depression during pregnancy. Prim Care Companion CNS Disord. 2015;17(2). https:\/\/www.psychiatrist.com\/pcc\/diagnosing-treating-depression-during-pregnancy\/"},{"issue":"2","key":"i2331-348X-30-3-323-b05","series-title":"Arch Pediatr Adolesc Med","first-page":"173","article-title":"Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants","volume":"160","author":"Levinson-Castiel","year":"2006","unstructured":"Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160(2):173\u2013176."},{"issue":"11","key":"i2331-348X-30-3-323-b06","series-title":"PLoS One","first-page":"e111327","article-title":"Neonatal adaptation in infants prenatally exposed to antidepressants\u2014clinical monitoring using Neonatal Abstinence Score","volume":"9","author":"Forsberg","year":"2014","unstructured":"Forsberg L, Nav\u00e9r L, Gustafsson LL, et al. Neonatal adaptation in infants prenatally exposed to antidepressants\u2014clinical monitoring using Neonatal Abstinence Score. PLoS One. 2014;9(11):e111327."},{"issue":"2","key":"i2331-348X-30-3-323-b07","series-title":"Isr J Psychiatry Relat Sci","first-page":"107","article-title":"Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome","volume":"45","author":"Klinger","year":"2008","unstructured":"Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci. 2008;45(2):107\u2013113."},{"key":"i2331-348X-30-3-323-b08","series-title":"StatPearls","article-title":"Neonatal abstinence syndrome","author":"Anbalagan","year":"2023","unstructured":"Anbalagan S, Mendez MD. Neonatal abstinence syndrome. In: StatPearls. StatPearls Publishing; 2023. Accessed July 24, 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551498\/"},{"issue":"6","key":"i2331-348X-30-3-323-b09","series-title":"Z Geburtshilfe Neonatol","first-page":"232","article-title":"Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy?","volume":"207","author":"Herbst","year":"2003","unstructured":"Herbst F, Gortner L. Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy? Z Geburtshilfe Neonatol. 2003;207(6):232\u2013234."},{"issue":"suppl 7","key":"i2331-348X-30-3-323-b10","series-title":"J Clin Psychiatry","first-page":"23","article-title":"Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome: Discontinuation Consensus Panel","volume":"58","author":"Schatzberg","year":"1997","unstructured":"Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome: Discontinuation Consensus Panel. J Clin Psychiatry. 1997;58(suppl 7):23\u201327."},{"issue":"3","key":"i2331-348X-30-3-323-b11","series-title":"J Affect Disord","first-page":"215","article-title":"Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects","volume":"51","author":"Stahl","year":"1998","unstructured":"Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215\u2013235."},{"key":"i2331-348X-30-3-323-b12","series-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","article-title":"Drug therapy of depression and anxiety disorders","author":"O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell JM, Bies RR, Williams AJ. Drug therapy of depression and anxiety disorders. In: Brunton LL, Knollmann BC, eds. Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023. Accessed May 22, 2023. https:\/\/accessmedicine.mhmedical.com\/book.aspx?bookid=3191&sectionid=269307357"},{"issue":"2","key":"i2331-348X-30-3-323-b13","series-title":"Psychother Psychosom","first-page":"72","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review","volume":"84","author":"Fava","year":"2015","unstructured":"Fava GA, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72\u201381."},{"issue":"6","key":"i2331-348X-30-3-323-b14","series-title":"Hum Psychopharmacol","first-page":"503","article-title":"New insights on the antidepressant discontinuation syndrome","volume":"29","author":"Harvey","year":"2014","unstructured":"Harvey BH, Slabbert FN. New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol. 2014;29(6):503\u2013516."},{"issue":"5","key":"i2331-348X-30-3-323-b15","series-title":"Psychother Psychosom","first-page":"299","article-title":"Neonatal withdrawal syndrome following late in utero exposure to selective serotonin reuptake inhibitors: a systematic review and meta-analysis of observational studies","volume":"90","author":"Wang","year":"2021","unstructured":"Wang J, Cosci F. Neonatal withdrawal syndrome following late in utero exposure to selective serotonin reuptake inhibitors: a systematic review and meta-analysis of observational studies. Psychother Psychosom. 2021;90(5):299\u2013307."},{"key":"i2331-348X-30-3-323-b16","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","first-page":"109668","article-title":"The role of NMDA receptor in neurobiology and treatment of major depressive disorder: evidence from translational research","volume":"94","author":"Amidfar","year":"2019","unstructured":"Amidfar M, Woelfer M, R\u00e9us GZ, et al. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: evidence from translational research. Prog Neuropsychopharmacol Biol Psychiatry. 2019;94:109668."},{"issue":"3","key":"i2331-348X-30-3-323-b17","series-title":"Nat Med","first-page":"238","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","unstructured":"Duman RS, Aghajanian GK, Sanacora G, et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238\u2013249."},{"issue":"10","key":"i2331-348X-30-3-323-b18","series-title":"Nat Rev Neurosci","first-page":"682","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","unstructured":"Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11(10):682\u2013696."},{"issue":"1","key":"i2331-348X-30-3-323-b19","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","first-page":"11","article-title":"Voxelwise meta-analysis of gray matter reduction in major depressive disorder","volume":"36","author":"Du","year":"2012","unstructured":"Du MY, Wu QZ, Yue Q, et al. Voxelwise meta-analysis of gray matter reduction in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(1):11\u201316."},{"key":"i2331-348X-30-3-323-b20","series-title":"Neurosci Biobehav Rev","first-page":"208","article-title":"Controversies on the role of 5-HT(2C) receptors in the mechanisms of action of antidepressant drugs","volume":"42","author":"Martin","year":"2014","unstructured":"Martin CBP, Hamon M, Lanfumey L, et al. Controversies on the role of 5-HT(2C) receptors in the mechanisms of action of antidepressant drugs. Neurosci Biobehav Rev. 2014;42:208\u2013223."},{"issue":"7","key":"i2331-348X-30-3-323-b21","series-title":"Psychoneuroendocrinology","first-page":"1019","article-title":"Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function","volume":"37","author":"Pawluski","year":"2012","unstructured":"Pawluski JL, Brain UM, Underhill CM, et al. Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function. Psychoneuroendocrinology. 2012;37(7):1019\u20131028."},{"key":"i2331-348X-30-3-323-b22","series-title":"Early Hum Dev","first-page":"37","article-title":"Is poor neonatal adaptation after exposure to antidepressant medication related to fetal cortisol levels: an explorative study","volume":"98","author":"Kieviet","year":"2016","unstructured":"Kieviet N, de Groot S, Noppe G, et al. Is poor neonatal adaptation after exposure to antidepressant medication related to fetal cortisol levels: an explorative study. Early Hum Dev. 2016;98:37\u201343."},{"issue":"5","key":"i2331-348X-30-3-323-b23","series-title":"J Clin Psychiatry","first-page":"605","article-title":"Neonatal discontinuation syndrome in serotonergic antidepressant-exposed neonates","volume":"78","author":"Yang","year":"2017","unstructured":"Yang A, Ciolino JD, Pinheiro E, et al. Neonatal discontinuation syndrome in serotonergic antidepressant-exposed neonates. J Clin Psychiatry. 2017;78(5):605\u2013611."},{"issue":"5","key":"i2331-348X-30-3-323-b24","series-title":"J Clin Psychopharmacol","first-page":"608","article-title":"Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy","volume":"32","author":"K\u00e4ll\u00e9n","year":"2012","unstructured":"K\u00e4ll\u00e9n B, Reis M. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol. 2012;32(5):608\u2013614."},{"issue":"7","key":"i2331-348X-30-3-323-b25","series-title":"Arch Gen Psychiatry","first-page":"720","article-title":"Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations","volume":"60","author":"Laine","year":"2003","unstructured":"Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60(7):720\u2013726."},{"issue":"9458","key":"i2331-348X-30-3-323-b26","series-title":"Lancet","first-page":"482","article-title":"Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis","volume":"365","author":"Sanz","year":"2005","unstructured":"Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365(9458):482\u2013487."},{"issue":"3","key":"i2331-348X-30-3-323-b27","series-title":"J Addict Med","first-page":"227","article-title":"Impact of in-utero exposure to selective serotonin reuptake inhibitors and opioids on neonatal opioid withdrawal syndrome","volume":"13","author":"Bhatt-Mehta","year":"2019","unstructured":"Bhatt-Mehta V, Richards J, Sturza J, et al. Impact of in-utero exposure to selective serotonin reuptake inhibitors and opioids on neonatal opioid withdrawal syndrome. J Addict Med. 2019;13(3):227\u2013234."},{"issue":"7","key":"i2331-348X-30-3-323-b28","series-title":"J Perinatol","first-page":"909","article-title":"Characteristics and outcomes of neonatal opioid withdrawal syndrome in preterm infants: a retrospective cohort study in the current era","volume":"43","author":"Heyward","year":"2023","unstructured":"Heyward A, Minich N, Hoffman AC, et al. Characteristics and outcomes of neonatal opioid withdrawal syndrome in preterm infants: a retrospective cohort study in the current era. J Perinatol. 2023;43(7):909\u2013915."},{"issue":"3","key":"i2331-348X-30-3-323-b29","series-title":"Pediatrics","first-page":"e600","article-title":"Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age","volume":"125","author":"Pedersen","year":"2010","unstructured":"Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics. 2010;125(3):e600\u2013e608."},{"issue":"10","key":"i2331-348X-30-3-323-b30","series-title":"JAMA Psychiatry","first-page":"1031","article-title":"Association of antidepressant medication use during pregnancy with intellectual disability in offspring","volume":"74","author":"Viktorin","year":"2017","unstructured":"Viktorin A, Uher R, Kolevzon A, et al. Association of antidepressant medication use during pregnancy with intellectual disability in offspring. JAMA Psychiatry. 2017;74(10):1031\u20131038."},{"issue":"9","key":"i2331-348X-30-3-323-b31","series-title":"J Perinatol","first-page":"615","article-title":"Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome","volume":"31","author":"Klinger","year":"2011","unstructured":"Klinger G, Frankenthal D, Merlob P, et al. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol. 2011;31(9):615\u2013620."},{"issue":"8","key":"i2331-348X-30-3-323-b32","series-title":"Early Hum Dev","first-page":"519","article-title":"Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect","volume":"89","author":"Hanley","year":"2013","unstructured":"Hanley GE, Brain U, Oberlander TF. Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect. Early Hum Dev. 2013;89(8):519\u2013524."},{"issue":"7","key":"i2331-348X-30-3-323-b33","series-title":"J Clin Psychiatry","first-page":"e842","article-title":"Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study","volume":"76","author":"Nulman","year":"2015","unstructured":"Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study. J Clin Psychiatry. 2015;76(7):e842\u2013e847."},{"issue":"6","key":"i2331-348X-30-3-323-b34","series-title":"Arch Dis Child Fetal Neonatal Ed","first-page":"F472","article-title":"Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation","volume":"97","author":"Sie","year":"2012","unstructured":"Sie SD, Wennink JMB, van Driel JJ, et al. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed. 2012;97(6):F472\u2013F476."},{"issue":"4","key":"i2331-348X-30-3-323-b35","series-title":"J Obstet Gynaecol Can","first-page":"348","article-title":"Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective seretonin\/norepinephrine reuptake inhibitors","volume":"31","author":"Koren","year":"2009","unstructured":"Koren G, Finkelstein Y, Matsui D, et al. Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective seretonin\/norepinephrine reuptake inhibitors. J Obstet Gynaecol Can. 2009;31(4):348\u2013350."},{"key":"i2331-348X-30-3-323-b36","series-title":"Neuropsychiatr Dis Treat","first-page":"1257","article-title":"The use of psychotropic medication during pregnancy: how about the newborn?","volume":"9","author":"Kieviet","year":"2013","unstructured":"Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr Dis Treat. 2013;9:1257\u20131266."},{"issue":"2","key":"i2331-348X-30-3-323-b37","series-title":"Pediatrics","first-page":"e540","article-title":"Neonatal drug withdrawal","volume":"129","author":"Hudak","year":"2012","unstructured":"Hudak ML, Tan RC, Committee on Drugs, et al. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540\u2013e560."},{"key":"i2331-348X-30-3-323-b38","series-title":"Obstet Gynecol","first-page":"1262","article-title":"Treatment and management of mental health conditions during pregnancy and postpartum","volume":"141","author":"Miller","year":"2023","unstructured":"Miller ES, Metz T, Moore-Simas TA, et al. Treatment and management of mental health conditions during pregnancy and postpartum. Obstet Gynecol. 2023;141:1262\u20131288."},{"issue":"3","key":"i2331-348X-30-3-323-b39","series-title":"Am Fam Physician","first-page":"449","article-title":"Antidepressant discontinuation syndrome","volume":"74","author":"Warner","year":"2006","unstructured":"Warner CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. Am Fam Physician. 2006;74(3):449\u2013456."},{"issue":"5","key":"i2331-348X-30-3-323-b40","series-title":"J Pediatr Pharmacol Ther","first-page":"502","article-title":"Serotonin toxicity versus withdrawal: clonidine one size fits all?","volume":"26","author":"Burdine","year":"2021","unstructured":"Burdine J, Luedtke S. Serotonin toxicity versus withdrawal: clonidine one size fits all? J Pediatr Pharmacol Ther. 2021;26(5):502\u2013517."},{"issue":"1_MeetingAbstract","key":"i2331-348X-30-3-323-b41","series-title":"Pediatrics","first-page":"223","article-title":"Clonidine to treat neonatal withdrawal due to in-utero venlafaxine exposure","volume":"142","author":"Rivera-Hernandez","year":"2018","unstructured":"Rivera-Hernandez P, Quin J, Slater-Myer L. Clonidine to treat neonatal withdrawal due to in-utero venlafaxine exposure. Pediatrics. 2018;142(1_MeetingAbstract):223."},{"issue":"7\u20138","key":"i2331-348X-30-3-323-b42","series-title":"Ann Pharmacother","first-page":"1342","article-title":"Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol","volume":"44","author":"O\u2019Mara","year":"2010","unstructured":"O\u2019Mara K, Gal P, Davanzo C. Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol. Ann Pharmacother. 2010;44(7\u20138):1342\u20131344."},{"issue":"6","key":"i2331-348X-30-3-323-b43","series-title":"Nurs Womens Health","first-page":"509","article-title":"Management of neonatal abstinence syndrome in the newborn nursery","volume":"18","author":"Artigas","year":"2014","unstructured":"Artigas V. Management of neonatal abstinence syndrome in the newborn nursery. Nurs Womens Health. 2014;18(6):509\u2013514."},{"key":"i2331-348X-30-3-323-b44","article-title":"Clonidine (catapres hydrocloride) [prescribing information]","year":"1974","unstructured":"Clonidine (catapres hydrocloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories; 1974. Revised March 2018."},{"issue":"3","key":"i2331-348X-30-3-323-b45","series-title":"Acta Paediatr","first-page":"288","article-title":"Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors","volume":"90","author":"Nordeng","year":"2001","unstructured":"Nordeng H, Lindemann R, Perminov KV, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90(3):288\u2013291."},{"issue":"10","key":"i2331-348X-30-3-323-b46","series-title":"Acta Paediatr","first-page":"1358","article-title":"Comparison of chlorpromazine versus morphine hydrochloride for treatment of neonatal abstinence syndrome","volume":"97","author":"Mazurier","year":"2008","unstructured":"Mazurier E, Cambonie G, Barbotte E, et al. Comparison of chlorpromazine versus morphine hydrochloride for treatment of neonatal abstinence syndrome. Acta Paediatr. 2008;97(10):1358\u20131361."},{"key":"i2331-348X-30-3-323-b47","series-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","article-title":"Hypnotics and sedatives","author":"O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell JM, Bies RR, Williams AJ. Hypnotics and sedatives. In: Brunton LL, Knollmann BC, eds. Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023. Accessed May 22, 2023. https:\/\/accessmedicine.mhmedical.com\/content.aspx?sectionid=269719266&bookid=3191#269719380"},{"issue":"5","key":"i2331-348X-30-3-323-b48","series-title":"Cochrane Database Syst Rev","first-page":"CD002053","article-title":"Sedatives for opioid withdrawal in newborn infants","volume":"2021","author":"Zankl","year":"2021","unstructured":"Zankl A, Martin J, Davey JG, et al. Sedatives for opioid withdrawal in newborn infants. Cochrane Database Syst Rev. 2021;2021(5):CD002053."},{"issue":"1","key":"i2331-348X-30-3-323-b49","series-title":"Eur J Pediatr","first-page":"141","article-title":"Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial","volume":"179","author":"Zimmermann","year":"2020","unstructured":"Zimmermann U, Rudin C, Du\u00f2 A, et al. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. Eur J Pediatr. 2020;179(1):141\u2013149."},{"key":"i2331-348X-30-3-323-b50","series-title":"NeoReviews","first-page":"222","article-title":"Neonatal abstinence syndrome","volume":"10","author":"Burgos","year":"2009","unstructured":"Burgos A, Burke B. Neonatal abstinence syndrome. NeoReviews. 2009;10:222\u2013229."},{"issue":"6","key":"i2331-348X-30-3-323-b51","series-title":"J Pediatr Pharmacol Ther","first-page":"522","article-title":"Neonatal toxicity from escitalopram use in utero: a case report","volume":"21","author":"Degiacomo","year":"2016","unstructured":"Degiacomo J, Luedtke S. Neonatal toxicity from escitalopram use in utero: a case report. J Pediatr Pharmacol Ther. 2016;21(6):522\u2013526."},{"issue":"5","key":"i2331-348X-30-3-323-b52","series-title":"Semin Fetal Neonatal Med","first-page":"321","article-title":"The use of phenobarbital and other anti-seizure drugs in newborns","volume":"22","author":"El-Dib","year":"2017","unstructured":"El-Dib M, Soul JS. The use of phenobarbital and other anti-seizure drugs in newborns. Semin Fetal Neonatal Med. 2017;22(5):321\u2013327."},{"issue":"3","key":"i2331-348X-30-3-323-b53","series-title":"Pharmaceutics","first-page":"301","article-title":"What is the best predictor of phenobarbital pharmacokinetics to use for initial dosing in neonates?","volume":"13","author":"\u0160\u00edma","year":"2021","unstructured":"\u0160\u00edma M, Michali\u010dkov\u00e1 D, Slana\u0159 O. What is the best predictor of phenobarbital pharmacokinetics to use for initial dosing in neonates? Pharmaceutics. 2021;13(3):301."},{"issue":"4","key":"i2331-348X-30-3-323-b54","series-title":"Arch Dis Child","first-page":"377","article-title":"Therapeutic drug monitoring in neonates","volume":"101","author":"Pauwels","year":"2016","unstructured":"Pauwels S, Allegaert K. Therapeutic drug monitoring in neonates. Arch Dis Child. 2016;101(4):377\u2013381."},{"issue":"11","key":"i2331-348X-30-3-323-b55","series-title":"J Perinatol","first-page":"841","article-title":"Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures","volume":"33","author":"Maitre","year":"2013","unstructured":"Maitre NL, Smolinsky C, Slaughter JC, et al. Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. J Perinatol. 2013;33(11):841\u2013846."},{"issue":"6","key":"i2331-348X-30-3-323-b56","series-title":"Pediatrics","first-page":"e20193182","article-title":"Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial","volume":"145","author":"Sharpe","year":"2020","unstructured":"Sharpe C, Reiner GE, Davis SL, et al. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics. 2020;145(6):e20193182."},{"issue":"8","key":"i2331-348X-30-3-323-b57","series-title":"JAMA Pediatr","first-page":"741","article-title":"Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial","volume":"172","author":"Davis","year":"2018","unstructured":"Davis JM, Shenberger J, Terrin N, et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatr. 2018;172(8):741\u2013748."},{"issue":"1","key":"i2331-348X-30-3-323-b58","series-title":"Drug Alcohol Depend","first-page":"31","article-title":"Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops","volume":"77","author":"Langenfeld","year":"2005","unstructured":"Langenfeld S, Birkenfeld L, Herkenrath P, et al. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend. 2005;77(1):31\u201336."},{"issue":"2","key":"i2331-348X-30-3-323-b59","series-title":"Pediatrics","first-page":"e547","article-title":"Neonatal abstinence syndrome","volume":"134","author":"Kocherlakota","year":"2014","unstructured":"Kocherlakota P. Neonatal abstinence syndrome. Pediatrics. 2014;134(2):e547\u2013e561."},{"issue":"4","key":"i2331-348X-30-3-323-b60","series-title":"J Perinatol","first-page":"278","article-title":"Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial","volume":"35","author":"Brown","year":"2015","unstructured":"Brown MS, Hayes MJ, Thornton LM. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol. 2015;35(4):278\u2013283."},{"issue":"1","key":"i2331-348X-30-3-323-b61","series-title":"Drug Alcohol Depend","first-page":"1","article-title":"Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome","volume":"79","author":"Jones","year":"2005","unstructured":"Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1):1\u201310."},{"issue":"24","key":"i2331-348X-30-3-323-b62","series-title":"N Engl J Med","first-page":"2320","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","unstructured":"Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320\u20132331."},{"issue":"3","key":"i2331-348X-30-3-323-b63","series-title":"J Pediatr Pharmacol Ther","first-page":"147","article-title":"Neonatal abstinence syndrome: essentials for the practitioner","volume":"19","author":"Siu","year":"2014","unstructured":"Siu A, Robinson CA. Neonatal abstinence syndrome: essentials for the practitioner. J Pediatr Pharmacol Ther. 2014;19(3):147\u2013155."},{"issue":"6","key":"i2331-348X-30-3-323-b64","series-title":"J Pediatr","first-page":"1221","article-title":"Cohort analysis of a pharmacokinetic-modeled methadone weaning optimization for neonatal abstinence syndrome","volume":"167","author":"Hall","year":"2015","unstructured":"Hall ES, Meinzen-Derr J, Wexelblatt SL. Cohort analysis of a pharmacokinetic-modeled methadone weaning optimization for neonatal abstinence syndrome. J Pediatr. 2015;167(6):1221\u20131225.e1."},{"issue":"2","key":"i2331-348X-30-3-323-b65","series-title":"Pediatr Crit Care Med","first-page":"162","article-title":"Effectiveness of a clinical pathway with methadone treatment protocol for treatment of neonatal abstinence syndrome following in utero drug exposure to substances of abuse*","volume":"15","author":"Bhatt-Mehta","year":"2014","unstructured":"Bhatt-Mehta V, Ng CM, Schumacher RE. Effectiveness of a clinical pathway with methadone treatment protocol for treatment of neonatal abstinence syndrome following in utero drug exposure to substances of abuse*. Pediatr Crit Care Med. 2014;15(2):162\u2013169."},{"issue":"2","key":"i2331-348X-30-3-323-b66","series-title":"J Addict Med","first-page":"113","article-title":"Stability of dilute oral morphine solution for neonatal abstinence syndrome","volume":"7","author":"Sauberan","year":"2013","unstructured":"Sauberan J, Rossi S, Kim JH. Stability of dilute oral morphine solution for neonatal abstinence syndrome. J Addict Med. 2013;7(2):113\u2013115."},{"key":"i2331-348X-30-3-323-b67","series-title":"J Perinatol","first-page":"1050","article-title":"Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome","volume":"40","author":"Brusseau","year":"2020","unstructured":"Brusseau C, Burnette T, Heidel RE. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. J Perinatol. 2020;40:1050\u20131055."},{"issue":"2","key":"i2331-348X-30-3-323-b68","series-title":"JMIR Ment Health","first-page":"e18","article-title":"A thematic analysis of stigma and disclosure for perinatal depression on an online forum","volume":"3","author":"Moore","year":"2016","unstructured":"Moore D, Ayers S, Drey N. A thematic analysis of stigma and disclosure for perinatal depression on an online forum. JMIR Ment Health. 2016;3(2):e18."},{"issue":"4","key":"i2331-348X-30-3-323-b69","series-title":"Obstet Gynecol Sci","first-page":"287","article-title":"Depression in pregnant and postpartum women during COVID-19 pandemic: systematic review and meta-analysis","volume":"65","author":"Adrianto","year":"2022","unstructured":"Adrianto N, Caesarlia J, Pajala FB. Depression in pregnant and postpartum women during COVID-19 pandemic: systematic review and meta-analysis. Obstet Gynecol Sci. 2022;65(4):287\u2013302."},{"key":"i2331-348X-30-3-323-b70","article-title":"Products - Data Briefs - Number 377","unstructured":"Products - Data Briefs - Number 377. Published September 8, 2020. Accessed May 11, 2023. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db377.htm"},{"issue":"2","key":"i2331-348X-30-3-323-b71","series-title":"Am J Obstet Gynecol","first-page":"194.e1-5","article-title":"Use of antidepressant medications during pregnancy: a multisite study","volume":"198","author":"Andrade","year":"2008","unstructured":"Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198(2):194.e1-5."},{"issue":"6","key":"i2331-348X-30-3-323-b72","series-title":"Am Fam Physician","first-page":"772","article-title":"ACOG guidelines on psychiatric medication use during pregnancy and lactation","volume":"78","author":"Armstrong","year":"2008","unstructured":"Armstrong C. ACOG guidelines on psychiatric medication use during pregnancy and lactation. Am Fam Physician. 2008;78(6):772\u2013778."},{"issue":"2","key":"i2331-348X-30-3-323-b73","series-title":"JAMA Pediatr","first-page":"200","article-title":"Neonatal abstinence syndrome incidence and health care costs in the United States, 2016","volume":"174","author":"Strahan","year":"2020","unstructured":"Strahan AE, Guy GP, Bohm M, et al. Neonatal abstinence syndrome incidence and health care costs in the United States, 2016. JAMA Pediatr. 2020;174(2):200\u2013202."},{"issue":"3","key":"i2331-348X-30-3-323-b01","series-title":"Gen Hosp Psychiatry","first-page":"265","article-title":"National trends in antidepressant medication treatment among publicly insured pregnant women","volume":"35","author":"Huybrechts","year":"2013","unstructured":"Huybrechts KF, Palmsten K, Mogun H, et al. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry. 2013;35(3):265\u2013271."},{"key":"i2331-348X-30-3-323-b02","series-title":"J Affect Disord","first-page":"86","article-title":"A systematic review and meta-regression of the prevalence and incidence of perinatal depression","volume":"219","author":"Woody","year":"2017","unstructured":"Woody CA, Ferrari AJ, Siskind DJ, et al. A systematic review and meta-regression of the prevalence and incidence of perinatal depression. J Affect Disord. 2017;219:86\u201392."},{"issue":"11","key":"i2331-348X-30-3-323-b03","series-title":"Can J Psychiatry","first-page":"726","article-title":"Perinatal risks of untreated depression during pregnancy","volume":"49","author":"Bonari","year":"2004","unstructured":"Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49(11):726\u2013735."},{"issue":"2","key":"i2331-348X-30-3-323-b04","series-title":"Prim Care Companion CNS Disord","article-title":"Diagnosing and treating depression during pregnancy","volume":"17","author":"Wichman","year":"2015","unstructured":"Wichman CL, Stern TA. Diagnosing and treating depression during pregnancy. Prim Care Companion CNS Disord. 2015;17(2). https:\/\/www.psychiatrist.com\/pcc\/diagnosing-treating-depression-during-pregnancy\/"},{"issue":"2","key":"i2331-348X-30-3-323-b05","series-title":"Arch Pediatr Adolesc Med","first-page":"173","article-title":"Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants","volume":"160","author":"Levinson-Castiel","year":"2006","unstructured":"Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160(2):173\u2013176."},{"issue":"11","key":"i2331-348X-30-3-323-b06","series-title":"PLoS One","first-page":"e111327","article-title":"Neonatal adaptation in infants prenatally exposed to antidepressants\u2014clinical monitoring using Neonatal Abstinence Score","volume":"9","author":"Forsberg","year":"2014","unstructured":"Forsberg L, Nav\u00e9r L, Gustafsson LL, et al. Neonatal adaptation in infants prenatally exposed to antidepressants\u2014clinical monitoring using Neonatal Abstinence Score. PLoS One. 2014;9(11):e111327."},{"issue":"2","key":"i2331-348X-30-3-323-b07","series-title":"Isr J Psychiatry Relat Sci","first-page":"107","article-title":"Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome","volume":"45","author":"Klinger","year":"2008","unstructured":"Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci. 2008;45(2):107\u2013113."},{"key":"i2331-348X-30-3-323-b08","series-title":"StatPearls","article-title":"Neonatal abstinence syndrome","author":"Anbalagan","year":"2023","unstructured":"Anbalagan S, Mendez MD. Neonatal abstinence syndrome. In: StatPearls. StatPearls Publishing; 2023. Accessed July 24, 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551498\/"},{"issue":"6","key":"i2331-348X-30-3-323-b09","series-title":"Z Geburtshilfe Neonatol","first-page":"232","article-title":"Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy?","volume":"207","author":"Herbst","year":"2003","unstructured":"Herbst F, Gortner L. Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy? Z Geburtshilfe Neonatol. 2003;207(6):232\u2013234."},{"issue":"suppl 7","key":"i2331-348X-30-3-323-b10","series-title":"J Clin Psychiatry","first-page":"23","article-title":"Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome: Discontinuation Consensus Panel","volume":"58","author":"Schatzberg","year":"1997","unstructured":"Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome: Discontinuation Consensus Panel. J Clin Psychiatry. 1997;58(suppl 7):23\u201327."},{"issue":"3","key":"i2331-348X-30-3-323-b11","series-title":"J Affect Disord","first-page":"215","article-title":"Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects","volume":"51","author":"Stahl","year":"1998","unstructured":"Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215\u2013235."},{"key":"i2331-348X-30-3-323-b12","series-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","article-title":"Drug therapy of depression and anxiety disorders","author":"O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell JM, Bies RR, Williams AJ. Drug therapy of depression and anxiety disorders. In: Brunton LL, Knollmann BC, eds. Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023. Accessed May 22, 2023. https:\/\/accessmedicine.mhmedical.com\/book.aspx?bookid=3191&sectionid=269307357"},{"issue":"2","key":"i2331-348X-30-3-323-b13","series-title":"Psychother Psychosom","first-page":"72","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review","volume":"84","author":"Fava","year":"2015","unstructured":"Fava GA, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72\u201381."},{"issue":"6","key":"i2331-348X-30-3-323-b14","series-title":"Hum Psychopharmacol","first-page":"503","article-title":"New insights on the antidepressant discontinuation syndrome","volume":"29","author":"Harvey","year":"2014","unstructured":"Harvey BH, Slabbert FN. New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol. 2014;29(6):503\u2013516."},{"issue":"5","key":"i2331-348X-30-3-323-b15","series-title":"Psychother Psychosom","first-page":"299","article-title":"Neonatal withdrawal syndrome following late in utero exposure to selective serotonin reuptake inhibitors: a systematic review and meta-analysis of observational studies","volume":"90","author":"Wang","year":"2021","unstructured":"Wang J, Cosci F. Neonatal withdrawal syndrome following late in utero exposure to selective serotonin reuptake inhibitors: a systematic review and meta-analysis of observational studies. Psychother Psychosom. 2021;90(5):299\u2013307."},{"key":"i2331-348X-30-3-323-b16","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","first-page":"109668","article-title":"The role of NMDA receptor in neurobiology and treatment of major depressive disorder: evidence from translational research","volume":"94","author":"Amidfar","year":"2019","unstructured":"Amidfar M, Woelfer M, R\u00e9us GZ, et al. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: evidence from translational research. Prog Neuropsychopharmacol Biol Psychiatry. 2019;94:109668."},{"issue":"3","key":"i2331-348X-30-3-323-b17","series-title":"Nat Med","first-page":"238","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","unstructured":"Duman RS, Aghajanian GK, Sanacora G, et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238\u2013249."},{"issue":"10","key":"i2331-348X-30-3-323-b18","series-title":"Nat Rev Neurosci","first-page":"682","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","unstructured":"Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11(10):682\u2013696."},{"issue":"1","key":"i2331-348X-30-3-323-b19","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","first-page":"11","article-title":"Voxelwise meta-analysis of gray matter reduction in major depressive disorder","volume":"36","author":"Du","year":"2012","unstructured":"Du MY, Wu QZ, Yue Q, et al. Voxelwise meta-analysis of gray matter reduction in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(1):11\u201316."},{"key":"i2331-348X-30-3-323-b20","series-title":"Neurosci Biobehav Rev","first-page":"208","article-title":"Controversies on the role of 5-HT(2C) receptors in the mechanisms of action of antidepressant drugs","volume":"42","author":"Martin","year":"2014","unstructured":"Martin CBP, Hamon M, Lanfumey L, et al. Controversies on the role of 5-HT(2C) receptors in the mechanisms of action of antidepressant drugs. Neurosci Biobehav Rev. 2014;42:208\u2013223."},{"issue":"7","key":"i2331-348X-30-3-323-b21","series-title":"Psychoneuroendocrinology","first-page":"1019","article-title":"Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function","volume":"37","author":"Pawluski","year":"2012","unstructured":"Pawluski JL, Brain UM, Underhill CM, et al. Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function. Psychoneuroendocrinology. 2012;37(7):1019\u20131028."},{"key":"i2331-348X-30-3-323-b22","series-title":"Early Hum Dev","first-page":"37","article-title":"Is poor neonatal adaptation after exposure to antidepressant medication related to fetal cortisol levels: an explorative study","volume":"98","author":"Kieviet","year":"2016","unstructured":"Kieviet N, de Groot S, Noppe G, et al. Is poor neonatal adaptation after exposure to antidepressant medication related to fetal cortisol levels: an explorative study. Early Hum Dev. 2016;98:37\u201343."},{"issue":"5","key":"i2331-348X-30-3-323-b23","series-title":"J Clin Psychiatry","first-page":"605","article-title":"Neonatal discontinuation syndrome in serotonergic antidepressant-exposed neonates","volume":"78","author":"Yang","year":"2017","unstructured":"Yang A, Ciolino JD, Pinheiro E, et al. Neonatal discontinuation syndrome in serotonergic antidepressant-exposed neonates. J Clin Psychiatry. 2017;78(5):605\u2013611."},{"issue":"5","key":"i2331-348X-30-3-323-b24","series-title":"J Clin Psychopharmacol","first-page":"608","article-title":"Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy","volume":"32","author":"K\u00e4ll\u00e9n","year":"2012","unstructured":"K\u00e4ll\u00e9n B, Reis M. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol. 2012;32(5):608\u2013614."},{"issue":"7","key":"i2331-348X-30-3-323-b25","series-title":"Arch Gen Psychiatry","first-page":"720","article-title":"Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations","volume":"60","author":"Laine","year":"2003","unstructured":"Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60(7):720\u2013726."},{"issue":"9458","key":"i2331-348X-30-3-323-b26","series-title":"Lancet","first-page":"482","article-title":"Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis","volume":"365","author":"Sanz","year":"2005","unstructured":"Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365(9458):482\u2013487."},{"issue":"3","key":"i2331-348X-30-3-323-b27","series-title":"J Addict Med","first-page":"227","article-title":"Impact of in-utero exposure to selective serotonin reuptake inhibitors and opioids on neonatal opioid withdrawal syndrome","volume":"13","author":"Bhatt-Mehta","year":"2019","unstructured":"Bhatt-Mehta V, Richards J, Sturza J, et al. Impact of in-utero exposure to selective serotonin reuptake inhibitors and opioids on neonatal opioid withdrawal syndrome. J Addict Med. 2019;13(3):227\u2013234."},{"issue":"7","key":"i2331-348X-30-3-323-b28","series-title":"J Perinatol","first-page":"909","article-title":"Characteristics and outcomes of neonatal opioid withdrawal syndrome in preterm infants: a retrospective cohort study in the current era","volume":"43","author":"Heyward","year":"2023","unstructured":"Heyward A, Minich N, Hoffman AC, et al. Characteristics and outcomes of neonatal opioid withdrawal syndrome in preterm infants: a retrospective cohort study in the current era. J Perinatol. 2023;43(7):909\u2013915."},{"issue":"3","key":"i2331-348X-30-3-323-b29","series-title":"Pediatrics","first-page":"e600","article-title":"Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age","volume":"125","author":"Pedersen","year":"2010","unstructured":"Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics. 2010;125(3):e600\u2013e608."},{"issue":"10","key":"i2331-348X-30-3-323-b30","series-title":"JAMA Psychiatry","first-page":"1031","article-title":"Association of antidepressant medication use during pregnancy with intellectual disability in offspring","volume":"74","author":"Viktorin","year":"2017","unstructured":"Viktorin A, Uher R, Kolevzon A, et al. Association of antidepressant medication use during pregnancy with intellectual disability in offspring. JAMA Psychiatry. 2017;74(10):1031\u20131038."},{"issue":"9","key":"i2331-348X-30-3-323-b31","series-title":"J Perinatol","first-page":"615","article-title":"Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome","volume":"31","author":"Klinger","year":"2011","unstructured":"Klinger G, Frankenthal D, Merlob P, et al. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol. 2011;31(9):615\u2013620."},{"issue":"8","key":"i2331-348X-30-3-323-b32","series-title":"Early Hum Dev","first-page":"519","article-title":"Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect","volume":"89","author":"Hanley","year":"2013","unstructured":"Hanley GE, Brain U, Oberlander TF. Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect. Early Hum Dev. 2013;89(8):519\u2013524."},{"issue":"7","key":"i2331-348X-30-3-323-b33","series-title":"J Clin Psychiatry","first-page":"e842","article-title":"Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study","volume":"76","author":"Nulman","year":"2015","unstructured":"Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study. J Clin Psychiatry. 2015;76(7):e842\u2013e847."},{"issue":"6","key":"i2331-348X-30-3-323-b34","series-title":"Arch Dis Child Fetal Neonatal Ed","first-page":"F472","article-title":"Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation","volume":"97","author":"Sie","year":"2012","unstructured":"Sie SD, Wennink JMB, van Driel JJ, et al. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed. 2012;97(6):F472\u2013F476."},{"issue":"4","key":"i2331-348X-30-3-323-b35","series-title":"J Obstet Gynaecol Can","first-page":"348","article-title":"Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective seretonin\/norepinephrine reuptake inhibitors","volume":"31","author":"Koren","year":"2009","unstructured":"Koren G, Finkelstein Y, Matsui D, et al. Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective seretonin\/norepinephrine reuptake inhibitors. J Obstet Gynaecol Can. 2009;31(4):348\u2013350."},{"key":"i2331-348X-30-3-323-b36","series-title":"Neuropsychiatr Dis Treat","first-page":"1257","article-title":"The use of psychotropic medication during pregnancy: how about the newborn?","volume":"9","author":"Kieviet","year":"2013","unstructured":"Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr Dis Treat. 2013;9:1257\u20131266."},{"issue":"2","key":"i2331-348X-30-3-323-b37","series-title":"Pediatrics","first-page":"e540","article-title":"Neonatal drug withdrawal","volume":"129","author":"Hudak","year":"2012","unstructured":"Hudak ML, Tan RC, Committee on Drugs, et al. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540\u2013e560."},{"key":"i2331-348X-30-3-323-b38","series-title":"Obstet Gynecol","first-page":"1262","article-title":"Treatment and management of mental health conditions during pregnancy and postpartum","volume":"141","author":"Miller","year":"2023","unstructured":"Miller ES, Metz T, Moore-Simas TA, et al. Treatment and management of mental health conditions during pregnancy and postpartum. Obstet Gynecol. 2023;141:1262\u20131288."},{"issue":"3","key":"i2331-348X-30-3-323-b39","series-title":"Am Fam Physician","first-page":"449","article-title":"Antidepressant discontinuation syndrome","volume":"74","author":"Warner","year":"2006","unstructured":"Warner CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. Am Fam Physician. 2006;74(3):449\u2013456."},{"issue":"5","key":"i2331-348X-30-3-323-b40","series-title":"J Pediatr Pharmacol Ther","first-page":"502","article-title":"Serotonin toxicity versus withdrawal: clonidine one size fits all?","volume":"26","author":"Burdine","year":"2021","unstructured":"Burdine J, Luedtke S. Serotonin toxicity versus withdrawal: clonidine one size fits all? J Pediatr Pharmacol Ther. 2021;26(5):502\u2013517."},{"issue":"1_MeetingAbstract","key":"i2331-348X-30-3-323-b41","series-title":"Pediatrics","first-page":"223","article-title":"Clonidine to treat neonatal withdrawal due to in-utero venlafaxine exposure","volume":"142","author":"Rivera-Hernandez","year":"2018","unstructured":"Rivera-Hernandez P, Quin J, Slater-Myer L. Clonidine to treat neonatal withdrawal due to in-utero venlafaxine exposure. Pediatrics. 2018;142(1_MeetingAbstract):223."},{"issue":"7\u20138","key":"i2331-348X-30-3-323-b42","series-title":"Ann Pharmacother","first-page":"1342","article-title":"Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol","volume":"44","author":"O\u2019Mara","year":"2010","unstructured":"O\u2019Mara K, Gal P, Davanzo C. Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol. Ann Pharmacother. 2010;44(7\u20138):1342\u20131344."},{"issue":"6","key":"i2331-348X-30-3-323-b43","series-title":"Nurs Womens Health","first-page":"509","article-title":"Management of neonatal abstinence syndrome in the newborn nursery","volume":"18","author":"Artigas","year":"2014","unstructured":"Artigas V. Management of neonatal abstinence syndrome in the newborn nursery. Nurs Womens Health. 2014;18(6):509\u2013514."},{"key":"i2331-348X-30-3-323-b44","article-title":"Clonidine (catapres hydrocloride) [prescribing information]","year":"1974","unstructured":"Clonidine (catapres hydrocloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories; 1974. Revised March 2018."},{"issue":"3","key":"i2331-348X-30-3-323-b45","series-title":"Acta Paediatr","first-page":"288","article-title":"Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors","volume":"90","author":"Nordeng","year":"2001","unstructured":"Nordeng H, Lindemann R, Perminov KV, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90(3):288\u2013291."},{"issue":"10","key":"i2331-348X-30-3-323-b46","series-title":"Acta Paediatr","first-page":"1358","article-title":"Comparison of chlorpromazine versus morphine hydrochloride for treatment of neonatal abstinence syndrome","volume":"97","author":"Mazurier","year":"2008","unstructured":"Mazurier E, Cambonie G, Barbotte E, et al. Comparison of chlorpromazine versus morphine hydrochloride for treatment of neonatal abstinence syndrome. Acta Paediatr. 2008;97(10):1358\u20131361."},{"key":"i2331-348X-30-3-323-b47","series-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","article-title":"Hypnotics and sedatives","author":"O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell JM, Bies RR, Williams AJ. Hypnotics and sedatives. In: Brunton LL, Knollmann BC, eds. Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023. Accessed May 22, 2023. https:\/\/accessmedicine.mhmedical.com\/content.aspx?sectionid=269719266&bookid=3191#269719380"},{"issue":"5","key":"i2331-348X-30-3-323-b48","series-title":"Cochrane Database Syst Rev","first-page":"CD002053","article-title":"Sedatives for opioid withdrawal in newborn infants","volume":"2021","author":"Zankl","year":"2021","unstructured":"Zankl A, Martin J, Davey JG, et al. Sedatives for opioid withdrawal in newborn infants. Cochrane Database Syst Rev. 2021;2021(5):CD002053."},{"issue":"1","key":"i2331-348X-30-3-323-b49","series-title":"Eur J Pediatr","first-page":"141","article-title":"Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial","volume":"179","author":"Zimmermann","year":"2020","unstructured":"Zimmermann U, Rudin C, Du\u00f2 A, et al. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. Eur J Pediatr. 2020;179(1):141\u2013149."},{"key":"i2331-348X-30-3-323-b50","series-title":"NeoReviews","first-page":"222","article-title":"Neonatal abstinence syndrome","volume":"10","author":"Burgos","year":"2009","unstructured":"Burgos A, Burke B. Neonatal abstinence syndrome. NeoReviews. 2009;10:222\u2013229."},{"issue":"6","key":"i2331-348X-30-3-323-b51","series-title":"J Pediatr Pharmacol Ther","first-page":"522","article-title":"Neonatal toxicity from escitalopram use in utero: a case report","volume":"21","author":"Degiacomo","year":"2016","unstructured":"Degiacomo J, Luedtke S. Neonatal toxicity from escitalopram use in utero: a case report. J Pediatr Pharmacol Ther. 2016;21(6):522\u2013526."},{"issue":"5","key":"i2331-348X-30-3-323-b52","series-title":"Semin Fetal Neonatal Med","first-page":"321","article-title":"The use of phenobarbital and other anti-seizure drugs in newborns","volume":"22","author":"El-Dib","year":"2017","unstructured":"El-Dib M, Soul JS. The use of phenobarbital and other anti-seizure drugs in newborns. Semin Fetal Neonatal Med. 2017;22(5):321\u2013327."},{"issue":"3","key":"i2331-348X-30-3-323-b53","series-title":"Pharmaceutics","first-page":"301","article-title":"What is the best predictor of phenobarbital pharmacokinetics to use for initial dosing in neonates?","volume":"13","author":"\u0160\u00edma","year":"2021","unstructured":"\u0160\u00edma M, Michali\u010dkov\u00e1 D, Slana\u0159 O. What is the best predictor of phenobarbital pharmacokinetics to use for initial dosing in neonates? Pharmaceutics. 2021;13(3):301."},{"issue":"4","key":"i2331-348X-30-3-323-b54","series-title":"Arch Dis Child","first-page":"377","article-title":"Therapeutic drug monitoring in neonates","volume":"101","author":"Pauwels","year":"2016","unstructured":"Pauwels S, Allegaert K. Therapeutic drug monitoring in neonates. Arch Dis Child. 2016;101(4):377\u2013381."},{"issue":"11","key":"i2331-348X-30-3-323-b55","series-title":"J Perinatol","first-page":"841","article-title":"Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures","volume":"33","author":"Maitre","year":"2013","unstructured":"Maitre NL, Smolinsky C, Slaughter JC, et al. Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. J Perinatol. 2013;33(11):841\u2013846."},{"issue":"6","key":"i2331-348X-30-3-323-b56","series-title":"Pediatrics","first-page":"e20193182","article-title":"Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial","volume":"145","author":"Sharpe","year":"2020","unstructured":"Sharpe C, Reiner GE, Davis SL, et al. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics. 2020;145(6):e20193182."},{"issue":"8","key":"i2331-348X-30-3-323-b57","series-title":"JAMA Pediatr","first-page":"741","article-title":"Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial","volume":"172","author":"Davis","year":"2018","unstructured":"Davis JM, Shenberger J, Terrin N, et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatr. 2018;172(8):741\u2013748."},{"issue":"1","key":"i2331-348X-30-3-323-b58","series-title":"Drug Alcohol Depend","first-page":"31","article-title":"Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops","volume":"77","author":"Langenfeld","year":"2005","unstructured":"Langenfeld S, Birkenfeld L, Herkenrath P, et al. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend. 2005;77(1):31\u201336."},{"issue":"2","key":"i2331-348X-30-3-323-b59","series-title":"Pediatrics","first-page":"e547","article-title":"Neonatal abstinence syndrome","volume":"134","author":"Kocherlakota","year":"2014","unstructured":"Kocherlakota P. Neonatal abstinence syndrome. Pediatrics. 2014;134(2):e547\u2013e561."},{"issue":"4","key":"i2331-348X-30-3-323-b60","series-title":"J Perinatol","first-page":"278","article-title":"Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial","volume":"35","author":"Brown","year":"2015","unstructured":"Brown MS, Hayes MJ, Thornton LM. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol. 2015;35(4):278\u2013283."},{"issue":"1","key":"i2331-348X-30-3-323-b61","series-title":"Drug Alcohol Depend","first-page":"1","article-title":"Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome","volume":"79","author":"Jones","year":"2005","unstructured":"Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1):1\u201310."},{"issue":"24","key":"i2331-348X-30-3-323-b62","series-title":"N Engl J Med","first-page":"2320","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","unstructured":"Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320\u20132331."},{"issue":"3","key":"i2331-348X-30-3-323-b63","series-title":"J Pediatr Pharmacol Ther","first-page":"147","article-title":"Neonatal abstinence syndrome: essentials for the practitioner","volume":"19","author":"Siu","year":"2014","unstructured":"Siu A, Robinson CA. Neonatal abstinence syndrome: essentials for the practitioner. J Pediatr Pharmacol Ther. 2014;19(3):147\u2013155."},{"issue":"6","key":"i2331-348X-30-3-323-b64","series-title":"J Pediatr","first-page":"1221","article-title":"Cohort analysis of a pharmacokinetic-modeled methadone weaning optimization for neonatal abstinence syndrome","volume":"167","author":"Hall","year":"2015","unstructured":"Hall ES, Meinzen-Derr J, Wexelblatt SL. Cohort analysis of a pharmacokinetic-modeled methadone weaning optimization for neonatal abstinence syndrome. J Pediatr. 2015;167(6):1221\u20131225.e1."},{"issue":"2","key":"i2331-348X-30-3-323-b65","series-title":"Pediatr Crit Care Med","first-page":"162","article-title":"Effectiveness of a clinical pathway with methadone treatment protocol for treatment of neonatal abstinence syndrome following in utero drug exposure to substances of abuse*","volume":"15","author":"Bhatt-Mehta","year":"2014","unstructured":"Bhatt-Mehta V, Ng CM, Schumacher RE. Effectiveness of a clinical pathway with methadone treatment protocol for treatment of neonatal abstinence syndrome following in utero drug exposure to substances of abuse*. Pediatr Crit Care Med. 2014;15(2):162\u2013169."},{"issue":"2","key":"i2331-348X-30-3-323-b66","series-title":"J Addict Med","first-page":"113","article-title":"Stability of dilute oral morphine solution for neonatal abstinence syndrome","volume":"7","author":"Sauberan","year":"2013","unstructured":"Sauberan J, Rossi S, Kim JH. Stability of dilute oral morphine solution for neonatal abstinence syndrome. J Addict Med. 2013;7(2):113\u2013115."},{"key":"i2331-348X-30-3-323-b67","series-title":"J Perinatol","first-page":"1050","article-title":"Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome","volume":"40","author":"Brusseau","year":"2020","unstructured":"Brusseau C, Burnette T, Heidel RE. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. J Perinatol. 2020;40:1050\u20131055."},{"issue":"2","key":"i2331-348X-30-3-323-b68","series-title":"JMIR Ment Health","first-page":"e18","article-title":"A thematic analysis of stigma and disclosure for perinatal depression on an online forum","volume":"3","author":"Moore","year":"2016","unstructured":"Moore D, Ayers S, Drey N. A thematic analysis of stigma and disclosure for perinatal depression on an online forum. JMIR Ment Health. 2016;3(2):e18."},{"issue":"4","key":"i2331-348X-30-3-323-b69","series-title":"Obstet Gynecol Sci","first-page":"287","article-title":"Depression in pregnant and postpartum women during COVID-19 pandemic: systematic review and meta-analysis","volume":"65","author":"Adrianto","year":"2022","unstructured":"Adrianto N, Caesarlia J, Pajala FB. Depression in pregnant and postpartum women during COVID-19 pandemic: systematic review and meta-analysis. Obstet Gynecol Sci. 2022;65(4):287\u2013302."},{"key":"i2331-348X-30-3-323-b70","article-title":"Products - Data Briefs - Number 377","unstructured":"Products - Data Briefs - Number 377. Published September 8, 2020. Accessed May 11, 2023. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db377.htm"},{"issue":"2","key":"i2331-348X-30-3-323-b71","series-title":"Am J Obstet Gynecol","first-page":"194.e1-5","article-title":"Use of antidepressant medications during pregnancy: a multisite study","volume":"198","author":"Andrade","year":"2008","unstructured":"Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198(2):194.e1-5."},{"issue":"6","key":"i2331-348X-30-3-323-b72","series-title":"Am Fam Physician","first-page":"772","article-title":"ACOG guidelines on psychiatric medication use during pregnancy and lactation","volume":"78","author":"Armstrong","year":"2008","unstructured":"Armstrong C. ACOG guidelines on psychiatric medication use during pregnancy and lactation. Am Fam Physician. 2008;78(6):772\u2013778."},{"issue":"2","key":"i2331-348X-30-3-323-b73","series-title":"JAMA Pediatr","first-page":"200","article-title":"Neonatal abstinence syndrome incidence and health care costs in the United States, 2016","volume":"174","author":"Strahan","year":"2020","unstructured":"Strahan AE, Guy GP, Bohm M, et al. Neonatal abstinence syndrome incidence and health care costs in the United States, 2016. JAMA Pediatr. 2020;174(2):200\u2013202."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/3\/article-p323.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/3\/article-p323.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/3\/article-p323.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:51:34Z","timestamp":1770771094000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/3\/article-p323.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":146,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5863\/jppt-24-00010","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}